Literature DB >> 11275629

Adult-onset minimal change disease among Taiwanese: clinical features, therapeutic response, and prognosis.

J J Huang1, S C Hsu, F F Chen, J M Sung, C C Tseng, M C Wang.   

Abstract

There are some racial differences in the prevalence and prognosis of idiopathic nephrotic syndrome; however, reports about minimal change disease (MCD) in Chinese were rare. We retrospectively analyzed 123 Chinese adults with idiopathic nephrotic syndrome, who received percutaneous renal biopsy in our institution within the last 10 years. In total, 46 patients (37.4%) were compatible with the pathological diagnosis of MCD. The male to female ratio was 1.2:1. The mean age of onset was 30.9 years, and 80% of the patients with MCD were less than 40 years. The mean daily proteinuria was 10.2 g, and serum albumin was 1.8 mg/dl. Azotemia occurred in 16 (35%) of 46 cases; hypertension, 13%; and microscopic hematuria, 13%. High selectivity index for proteinuria (SI <0.1) was noted in 12 (39%) of 31 cases; and high IgE level was found in 83.7% of the study subjects, although only one case had allergic history. Complete remission in 36 MCD patients treated with corticosteroid was achieved by 42% (15/36), 80% (29/36), and 94% (34/36) within 4, 8, and 12 weeks, respectively. The time interval to remission was similar between the younger group (<40 years old, 1.7 months) and older group (>40 years old, 1.6 months). Nineteen (56%) of 34 cases with steroid response did not relapse, and the other cases (44%) had a mean relapse rate of 1.5 times per patient within a period of 45 months. The age of onset in MCD cases was not significantly correlated with steroid-responsive rate, and the time interval to remission. However, a tendency existed between the onset in the young age and the sequentially relapsing rate (p = 0.06). Two cases with primary steroid resistance and 5 cases with frequent relapse or steroid dependence responded well to intravenous pulse therapy of cyclophosphamide, except one refractory case. No thrombotic episode was ever noted in our group. Regarding infectious complications, primary peritonitis occurred in one, pneumonia in one, and cellulitis in 6 cases during active nephrotic stage. Two mortality cases, one with E. coli-related necrotizing fasciitis and one from pneumonia, were noted. In brief, compared with children, adult patients with MCD had lesser high selectivity index for proteinuria, the same steroid-responsive rate (94%), but slower response, and significantly lesser relapsing rate. The intravenous pulse therapy of cyclophosphamide may be an alternative regimen for adult patients with steroid resistance or dependency. In addition, the Asian adult-onset MCD had younger age, male predominance, and lesser relapsing rate in comparison to those of the Western population.

Entities:  

Mesh:

Year:  2001        PMID: 11275629     DOI: 10.1159/000046215

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  22 in total

1.  The characteristics of relapse in adult-onset minimal-change nephrotic syndrome.

Authors:  Takashi Takei; Minako Koike; Koichi Suzuki; Satsuki Shirota; Mitsuyo Itabashi; Shigeru Ohtsubo; Hidekazu Sugiura; Keiko Suzuki; Chiari Kojima; Masaki Takahashi; Jun Ino; Tetsuya Ogawa; Keiko Uchida; Ken Tsuchiya; Wako Yumura; Kosaku Nitta
Journal:  Clin Exp Nephrol       Date:  2007-09-28       Impact factor: 2.801

2.  The Evolving Role of Rituximab in Adult Minimal Change Glomerulopathy.

Authors:  Landon C Brown; Meghan A Jobson; Fernanda Payan Schober; Emily H Chang; Ronald J Falk; Patrick H Nachman; William F Pendergraft
Journal:  Am J Nephrol       Date:  2017-03-18       Impact factor: 3.754

3.  Age and prediction of remission and relapse of proteinuria and corticosteroid-related adverse events in adult-onset minimal-change disease: a retrospective cohort study.

Authors:  Maki Shinzawa; Ryohei Yamamoto; Yasuyuki Nagasawa; Susumu Oseto; Daisuke Mori; Kodo Tomida; Terumasa Hayashi; Masaaki Izumi; Megumu Fukunaga; Atsushi Yamauchi; Yoshiharu Tsubakihara; Hiromi Rakugi; Yoshitaka Isaka
Journal:  Clin Exp Nephrol       Date:  2013-03-20       Impact factor: 2.801

4.  Rituximab in adult patients with multi-relapsing/steroid-dependent minimal change disease and focal segmental glomerulosclerosis: a report of 5 cases.

Authors:  Andreas Kronbichler; Paul König; Martin Busch; Gunter Wolf; Gert Mayer; Michael Rudnicki
Journal:  Wien Klin Wochenschr       Date:  2013-04-27       Impact factor: 1.704

5.  T-cell receptor diversity in minimal change disease in the NEPTUNE study.

Authors:  Shiying Liu; William S Bush; Kristy Miskimen; Agustin Gonzalez-Vicente; Jessica N Cooke Bailey; Ioanna Konidari; Jacob L McCauley; John R Sedor; John F O'Toole; Dana C Crawford
Journal:  Pediatr Nephrol       Date:  2022-08-09       Impact factor: 3.651

6.  Demographic, clinical and laboratory characteristics of adult-onset minimal change disease in Turkey: Turkish Society of Nephrology-Glomerular Diseases (TSN-GOLD) Working Group.

Authors:  Zeki Aydin; Murvet Yilmaz; Murat Sipahioglu; Erkan Dervisoglu; Nihal Aydemir; Sami Uzun; Zulal Istemihan; Oktay Unsal; Erhan Tatar; Haci Bayram Berktas; Arzu Ozdemir; Abdullah Sumnu; Gizem Kumru; Hakki Cetinkaya; Sinan Kazan; Ismail Kocyigit; Cenk Gokalp; Baris Hasbal; Ayse Serra Artan; Ruya Ozelsancak; Dilek Taymez; Serap Yadigar; Selma Alagoz; Bilal Burcak Aslan; Selcuk Yaylaci; Jabrayil Jabrayilov; Kenan Turgutalp; Belda Dursun; Garip Sahin
Journal:  Int Urol Nephrol       Date:  2022-09-30       Impact factor: 2.266

7.  Comparison of methylprednisolone plus prednisolone with prednisolone alone as initial treatment in adult-onset minimal change disease: a retrospective cohort study.

Authors:  Maki Shinzawa; Ryohei Yamamoto; Yasuyuki Nagasawa; Susumu Oseto; Daisuke Mori; Kodo Tomida; Terumasa Hayashi; Masaaki Izumi; Megumu Fukunaga; Atsushi Yamauchi; Yoshiharu Tsubakihara; Yoshitaka Isaka
Journal:  Clin J Am Soc Nephrol       Date:  2014-04-10       Impact factor: 8.237

8.  Randomized, Controlled Trial of Tacrolimus and Prednisolone Monotherapy for Adults with De Novo Minimal Change Disease: A Multicenter, Randomized, Controlled Trial.

Authors:  Nicholas Rhys Medjeral-Thomas; Christopher Lawrence; Marie Condon; Bhrigu Sood; Paul Warwicker; Heather Brown; James Pattison; Sunil Bhandari; Jonathan Barratt; Neil Turner; H Terence Cook; Jeremy B Levy; Liz Lightstone; Charles Pusey; Jack Galliford; Thomas D Cairns; Megan Griffith
Journal:  Clin J Am Soc Nephrol       Date:  2020-01-17       Impact factor: 8.237

9.  Necrotizing fasciitis in a child: a rare complication of idiopathic nephrotic syndrome.

Authors:  Ali Delibaş; Kenan Bek; Mehmet Bülbül; Gülay Demircin; Sahika Baysun; Ayşe Oner
Journal:  Pediatr Nephrol       Date:  2004-11-10       Impact factor: 3.714

10.  Comparison of the Efficacy and Safety of Tacrolimus and Low-Dose Corticosteroid with High-Dose Corticosteroid for Minimal Change Nephrotic Syndrome in Adults.

Authors:  Ho Jun Chin; Dong-Wan Chae; Yong Chul Kim; Won Suk An; ChunGyoo Ihm; Dong-Chan Jin; Sung Gyun Kim; Yong-Lim Kim; Yong-Soo Kim; Yoon-Goo Kim; Ho Seok Koo; Jung Eun Lee; Kang Wook Lee; Jieun Oh; Jung Hwan Park; Hongsi Jiang; Hyuncheol Lee; Sang Koo Lee
Journal:  J Am Soc Nephrol       Date:  2020-11-09       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.